Dement Neurocogn Disord.  2017 Jun;16(2):40-47. 10.12779/dnd.2017.16.2.40.

Subjective Cognitive Decline and Alzheimer's Disease Spectrum Disorder

• Hong YJ
• Lee JH

• KMID: 2442825
• DOI: http://doi.org/10.12779/dnd.2017.16.2.40

Abstract

Subjective cognitive decline (SCD) represents subjective complaints about cognitive decline in the absence of objective impairment in neuropsychological tests. Recently, growing evidence has suggested that SCD might be the first symptomatic stage of Alzheimer's disease (AD) spectrum disorders. However, SCD is a heterogeneous condition mixed with AD and non-AD related conditions. Hence, refinement of evidence from previous reports and standardization of the concept about SCD are needed to define appropriate target population with AD pathology. In this article, we review previous studies involving subjects with SCD, the new proposed research criteria, and characteristics of SCD in the aspect of preclinical AD. Biomarker status of SCD is also addressed. Future researches on SCD require a longitudinal follow-up with sufficient biomarker studies and proper outcome measures.

Keyword

subjective cognitive decline; Alzheimer's disease; biomarker; preclinical stage

MeSH Terms

Alzheimer Disease*
Follow-Up Studies
Health Services Needs and Demand
Neuropsychological Tests
Outcome Assessment (Health Care)
Pathology

Reference

1. Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013; 12:207–216. PMID: 23332364.

2. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013; 12:357–367. PMID: 23477989.

3. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010; 9:1118–1127. PMID: 20934914.

4. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011; 7:263–269. PMID: 21514250.

5. Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chételat G, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement. 2014; 10:844–852. PMID: 24798886.

6. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7:280–292. PMID: 21514248.

7. Reisberg B, Ferris SH, de Leon MJ, Crook T. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982; 139:1136–1139. PMID: 7114305.

8. Rabin LA, Chi SY, Wang C, Fogel J, Kann SJ, Aronov A. Prospective memory on a novel clinical task in older adults with mild cognitive impairment and subjective cognitive decline. Neuropsychol Rehabil. 2014; 24:868–893. PMID: 24875614.

9. Loewenstein DA, Curiel RE, Greig MT, Bauer RM, Rosado M, Bowers D, et al. A novel cognitive stress test for the detection of preclinical Alzheimer disease: discriminative properties and relation to amyloid load. Am J Geriatr Psychiatry. 2016; 24:804–813. PMID: 27160985.

10. Dufouil C, Fuhrer R, Alpérovitch A. Subjective cognitive complaints and cognitive decline: consequence or predictor? The epidemiology of vascular aging study. J Am Geriatr Soc. 2005; 53:616–621. PMID: 15817007.

11. Glodzik-Sobanska L, Reisberg B, De Santi S, Babb JS, Pirraglia E, Rich KE, et al. Subjective memory complaints: presence, severity and future outcome in normal older subjects. Dement Geriatr Cogn Disord. 2007; 24:177–184. PMID: 17641528.

12. Jessen F, Wiese B, Bachmann C, Eifflaender-Gorfer S, Haller F, Kölsch H, et al. Prediction of dementia by subjective memory impairment: effects of severity and temporal association with cognitive impairment. Arch Gen Psychiatry. 2010; 67:414–422. PMID: 20368517.

13. Reisberg B, Shulman MB, Torossian C, Leng L, Zhu W. Outcome over seven years of healthy adults with and without subjective cognitive impairment. Alzheimers Dement. 2010; 6:11–24. PMID: 20129317.

14. Jessen F, Feyen L, Freymann K, Tepest R, Maier W, Heun R, et al. Volume reduction of the entorhinal cortex in subjective memory impairment. Neurobiol Aging. 2006; 27:1751–1756. PMID: 16309795.

15. Saykin AJ, Wishart HA, Rabin LA, Santulli RB, Flashman LA, West JD, et al. Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI. Neurology. 2006; 67:834–842. PMID: 16966547.

16. Scheef L, Spottke A, Daerr M, Joe A, Striepens N, Kölsch H, et al. Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment. Neurology. 2012; 79:1332–1339. PMID: 22914828.

17. Peter J, Scheef L, Abdulkadir A, Boecker H, Heneka M, Wagner M, et al. Gray matter atrophy pattern in elderly with subjective memory impairment. Alzheimers Dement. 2014; 10:99–108. PMID: 23867795.

18. Stenset V, Bjørnerud A, Fjell AM, Walhovd KB, Hofoss D, Due-Tønnessen P, et al. Cingulum fiber diffusivity and CSF t-tau in patients with subjective and mild cognitive impairment. Neurobiol Aging. 2011; 32:581–589. PMID: 19428143.

19. Selnes P, Fjell AM, Gjerstad L, Bjørnerud A, Wallin A, Due-Tønnessen P, et al. White matter imaging changes in subjective and mild cognitive impairment. Alzheimers Dement. 2012; 8(5 Suppl):S112–S121. PMID: 23021621.

20. Hong YJ, Yoon B, Shim YS, Ahn KJ, Yang DW, Lee JH. Gray and white matter degenerations in subjective memory impairment: comparisons with normal controls and mild cognitive impairment. J Korean Med Sci. 2015; 30:1652–1658. PMID: 26539011.

21. Hong YJ, Kim CM, Jang EH, Hwang J, Roh JH, Lee JH. White matter changes may precede gray matter loss in elderly with subjective memory impairment. Dement Geriatr Cogn Disord. 2016; 42:227–235. PMID: 27701163.

22. Mosconi L, De Santi S, Brys M, Tsui WH, Pirraglia E, Glodzik-Sobanska L, et al. Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. Biol Psychiatry. 2008; 63:609–618. PMID: 17720148.

23. Wang Y, Risacher SL, West JD, McDonald BC, Magee TR, Farlow MR, et al. Altered default mode network connectivity in older adults with cognitive complaints and amnestic mild cognitive impairment. J Alzheimers Dis. 2013; 35:751–760. PMID: 23481685.

24. Hong YJ, Yoon B, Shim YS, Kim SO, Kim HJ, Choi SH, et al. Predictors of clinical progression of subjective memory impairment in elderly subjects: data from the Clinical Research Centers for Dementia of South Korea (CREDOS). Dement Geriatr Cogn Disord. 2015; 40:158–165. PMID: 26088530.

25. Jonker C, Geerlings MI, Schmand B. Are memory complaints predictive for dementia? A review of clinical and population-based studies. Int J Geriatr Psychiatry. 2000; 15:983–991. PMID: 11113976.

26. Mewton L, Sachdev P, Anderson T, Sunderland M, Andrews G. Demographic, clinical, and lifestyle correlates of subjective memory complaints in the Australian population. Am J Geriatr Psychiatry. 2014; 22:1222–1232. PMID: 23880335.

27. Abdulrab K, Heun R. Subjective memory impairment. A review of its definitions indicates the need for a comprehensive set of standardised and validated criteria. Eur Psychiatry. 2008; 23:321–330. PMID: 18434102.

28. Rabin LA, Smart CM, Crane PK, Amariglio RE, Berman LM, Boada M, et al. Subjective cognitive decline in older adults: an overview of self-report measures used across 19 international research studies. J Alzheimers Dis. 2015; 48(Suppl 1):S63–S86. PMID: 26402085.

29. Rodda J, Okello A, Edison P, Dannhauser T, Brooks DJ, Walker Z. (11)C-PIB PET in subjective cognitive impairment. Eur Psychiatry. 2010; 25:123–125. PMID: 19926266.

30. Amariglio RE, Becker JA, Carmasin J, Wadsworth LP, Lorius N, Sullivan C, et al. Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia. 2012; 50:2880–2886. PMID: 22940426.

31. Perrotin A, Mormino EC, Madison CM, Hayenga AO, Jagust WJ. Subjective cognition and amyloid deposition imaging: a Pittsburgh compound B positron emission tomography study in normal elderly individuals. Arch Neurol. 2012; 69:223–229. PMID: 22332189.

32. Amariglio RE, Mormino EC, Pietras AC, Marshall GA, Vannini P, Johnson KA, et al. Subjective cognitive concerns, amyloid-β, and neurodegeneration in clinically normal elderly. Neurology. 2015; 85:56–62. PMID: 26048028.

33. Hollands S, Lim YY, Buckley R, Pietrzak RH, Snyder PJ, Ames D, et al. Amyloid-β related memory decline is not associated with subjective or informant rated cognitive impairment in healthy adults. J Alzheimers Dis. 2015; 43:677–686. PMID: 25114076.

34. Ivanoiu A, Dricot L, Gilis N, Grandin C, Lhommel R, Quenon L, et al. Classification of non-demented patients attending a memory clinic using the new diagnostic criteria for Alzheimer's disease with diseaserelated biomarkers. J Alzheimers Dis. 2015; 43:835–847. PMID: 25114071.

35. Risacher SL, Kim S, Nho K, Foroud T, Shen L, Petersen RC, et al. APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern. Alzheimers Dement. 2015; 11:1417–1429. PMID: 25960448.

36. Snitz BE, Lopez OL, McDade E, Becker JT, Cohen AD, Price JC, et al. Amyloid-β imaging in older adults presenting to a memory clinic with subjective cognitive decline: a pilot study. J Alzheimers Dis. 2015; 48(Suppl 1):S151–S159. PMID: 26402082.

37. Snitz BE, Weissfeld LA, Cohen AD, Lopez OL, Nebes RD, Aizenstein HJ, et al. Subjective cognitive complaints, personality and brain amyloid-beta in cognitively normal older adults. Am J Geriatr Psychiatry. 2015; 23:985–993. PMID: 25746485.

38. Zwan MD, Villemagne VL, Doré V, Buckley R, Bourgeat P, Veljanoski R, et al. Subjective memory complaints in APOEε4 carriers are associated with high amyloid-β burden. J Alzheimers Dis. 2016; 49:1115–1122. PMID: 26639956.

39. Buckley RF, Maruff P, Ames D, Bourgeat P, Martins RN, Masters CL, et al. Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease. Alzheimers Dement. 2016; 12:796–804. PMID: 26852195.

40. Merrill DA, Siddarth P, Raji CA, Emerson ND, Rueda F, Ercoli LM, et al. Modifiable risk factors and brain positron emission tomography measures of amyloid and tau in nondemented adults with memory complaints. Am J Geriatr Psychiatry. 2016; 24:729–737. PMID: 27421618.

41. Stomrud E, Hansson O, Blennow K, Minthon L, Londos E. Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. Dement Geriatr Cogn Disord. 2007; 24:118–124. PMID: 17622715.

42. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009; 8:619–627. PMID: 19523877.

43. Grambaite R, Stenset V, Reinvang I, Walhovd KB, Fjell AM, Fladby T. White matter diffusivity predicts memory in patients with subjective and mild cognitive impairment and normal CSF total tau levels. J Int Neuropsychol Soc. 2010; 16:58–69. PMID: 19835655.

44. Antonell A, Fortea J, Rami L, Bosch B, Balasa M, Sánchez-Valle R, et al. Different profiles of Alzheimer's disease cerebrospinal fluid biomarkers in controls and subjects with subjective memory complaints. J Neural Transm (Vienna). 2011; 118:259–262. PMID: 21161712.

45. Rolstad S, Berg AI, Bjerke M, Blennow K, Johansson B, Zetterberg H, et al. Amyloid-β₄₂ is associated with cognitive impairment in healthy elderly and subjective cognitive impairment. J Alzheimers Dis. 2011; 26:135–142.

46. Grambaite R, Hessen E, Auning E, Aarsland D, Selnes P, Fladby T. Correlates of subjective and mild cognitive impairment: depressive symptoms and CSF biomarkers. Dement Geriatr Cogn Dis Extra. 2013; 3:291–300. PMID: 24174924.

47. Selnes P, Aarsland D, Bjørnerud A, Gjerstad L, Wallin A, Hessen E, et al. Diffusion tensor imaging surpasses cerebrospinal fluid as predictor of cognitive decline and medial temporal lobe atrophy in subjective cognitive impairment and mild cognitive impairment. J Alzheimers Dis. 2013; 33:723–736. PMID: 23186987.

48. van Harten AC, Smits LL, Teunissen CE, Visser PJ, Koene T, Blankenstein MA, et al. Preclinical AD predicts decline in memory and executive functions in subjective complaints. Neurology. 2013; 81:1409–1416. PMID: 24049134.

49. van Harten AC, Visser PJ, Pijnenburg YA, Teunissen CE, Blankenstein MA, Scheltens P, et al. Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints. Alzheimers Dement. 2013; 9:481–487. PMID: 23232269.

50. Hessen E, Nordlund A, Stålhammar J, Eckerström M, Bjerke M, Eckerström C, et al. T-tau is associated with objective memory decline over two years in persons seeking help for subjective cognitive decline: a report from the Gothenburg-Oslo MCI study. J Alzheimers Dis. 2015; 47:619–628. PMID: 26401697.

51. Toledo JB, Bjerke M, Chen K, Rozycki M, Jack CR Jr, Weiner MW, et al. Memory, executive, and multidomain subtle cognitive impairment: clinical and biomarker findings. Neurology. 2015; 85:144–153. PMID: 26085606.

52. Valech N, Mollica MA, Olives J, Tort A, Fortea J, Lleo A, et al. Informants' perception of subjective cognitive decline helps to discriminate preclinical Alzheimer's disease from normal aging. J Alzheimers Dis. 2015; 48(Suppl 1):S87–S98. PMID: 26445275.

53. Mandecka M, Budziszewska M, Barczak A, PepłońZska B, Chodakowska-Żebrowska M, Filipek-Gliszczyńska A, et al. Association between cerebrospinal fluid biomarkers for Alzheimer's disease, APOE genotypes and auditory verbal learning task in subjective cognitive decline, mild cognitive impairment, and Alzheimer's disease. J Alzheimers Dis. 2016; 54:157–168. PMID: 27472875.

54. Sierra-Rio A, Balasa M, Olives J, Antonell A, Iranzo A, Castellví M, et al. Cerebrospinal fluid biomarkers predict clinical evolution in patients with subjective cognitive decline and mild cognitive impairment. Neurodegener Dis. 2016; 16:69–76. PMID: 26560503.

55. Colijn MA, Grossberg GT. Amyloid and tau biomarkers in subjective cognitive impairment. J Alzheimers Dis. 2015; 47:1–8. PMID: 26402749.

56. Lista S, Molinuevo JL, Cavedo E, Rami L, Amouyel P, Teipel SJ, et al. Evolving evidence for the value of neuroimaging methods and biological markers in subjects categorized with subjective cognitive decline. J Alzheimers Dis. 2015; 48(Suppl 1):S171–S191. PMID: 26402088.